-
公开(公告)号:US20190106486A1
公开(公告)日:2019-04-11
申请号:US16164509
申请日:2018-10-18
Applicant: Cephalon, Inc.
Inventor: Lynn Dorothy Poulton , Matthew Pollard , Anthony G. Doyle , Bridget Ann Cooksey , Vanya Pande , Adam William Clarke
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
-
公开(公告)号:US20170081400A1
公开(公告)日:2017-03-23
申请号:US15267213
申请日:2016-09-16
Applicant: Cephalon, Inc.
Inventor: Lynn Dorothy Poulton , Matthew Pollard , Anthony G. Doyle , Bridget Ann Cooksey , Vanya Pande , Adam William Clarke
IPC: C07K16/24
CPC classification number: C07K16/241 , A61K2039/505 , A61P11/06 , A61P37/06 , C07K16/2875 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
-
公开(公告)号:US20220185902A1
公开(公告)日:2022-06-16
申请号:US17538530
申请日:2021-11-30
Applicant: Cephalon, Inc.
Inventor: Lynn Dorothy POULTON , Matthew Pollard , Anthony G. Doyle , Bridget A. Cooksey , Vanya Pande , Adam W. Clarke
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
-
4.
公开(公告)号:US11220549B2
公开(公告)日:2022-01-11
申请号:US16164509
申请日:2018-10-18
Applicant: Cephalon, Inc.
Inventor: Lynn Dorothy Poulton , Matthew Pollard , Anthony G. Doyle , Bridget A. Cooksey , Vanya Pande , Adam W. Clarke
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
-
公开(公告)号:US10138296B2
公开(公告)日:2018-11-27
申请号:US15267213
申请日:2016-09-16
Applicant: Cephalon, Inc.
Inventor: Lynn Dorothy Poulton , Matthew Pollard , Anthony G. Doyle , Bridget Ann Cooksey , Vanya Pande , Adam William Clarke
IPC: C07K16/24 , C12N5/10 , C12N15/10 , C12N15/13 , C12N15/63 , G01N33/53 , C07K16/28 , A61P37/06 , A61P11/06 , A61K39/00
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
-
-
-
-